New Daily Pill Doubles Survival Time For Advanced Patients
A new once-daily pill has delivered one of the most significant advances in pancreatic cancer treatment in decades. Researchers reported that the experimental drug daraxonrasib nearly doubled survival time for patients with advanced pancreatic cancer whose disease had progressed after initial treatment. The findings were presented at the 2026 American Society of Clinical Oncology (ASCO)…
